10 results about "Atrial pacing" patented technology

Described herein are methods for use with an implantable system including at least an atrial leadless pacemaker (aLP). Also described herein are specific implementations of an aLP, as well as implantable systems including an aLP. In certain embodiments, the aLP senses a signal from which cardiac activity associated with a ventricular chamber can be detected by the aLP itself based on feature(s) of the sensed signal. The aLP monitors the sensed signal for an intrinsic or paced ventricular activation within a ventricular event monitor window. In response to the aLP detecting an intrinsic or paced ventricular activation itself from the sensed signal within the ventricular event monitor window, the aLP resets an atrial escape interval timer that is used by the aLP to time delivery of an atrial pacing pulse if an intrinsic atrial activation is not detected within an atrial escape interval.

A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.

A method of operating a cardiac rhythm management (CRM) system includes: measuring a baseline PR interval of cardiac depolarization; measuring one or both of the heart sound and the heart depolarized QRS width; delivering pacing stimulation according to atrial sensing of a ventricular pacing interval (AsVp interval), and measuring one or both of a heart sound and a QRS width of the AsVp interval, where the pacing stimulation is delivered using a conducted system pacing (CSP) vector comprising electrodes positioned in the interventricular septum; delivering a pacing stimulus according to an atrial pacing to ventricular pacing interval (ApVp interval) and measuring one or both of a heart sound and a QRS width of the ApVp interval; and generating a recommended atrial-to-ventricular delay setting for the CSP based on one or both of the measured heart sound and the QRS width.

A dual chamber LP system (100) includes an aLP (102a) and a vLP (102b) that collectively provide AAI+VVI operation, and selectively transition from the AAI+VVI operation to collectively providing coordinated dual chamber operation (e.g., DDD operation, but not limited thereto), and vice versa. While providing the AAI operation, the aLP (102a) performs atrial pacing when an intrinsic atrial event is not detected within a specified AA interval, performs atrial sensing, and inhibits the atrial pacing when the intrinsic atrial event is detected within the specified AA interval. While providing the VVI operation, the vLP (102b) performs ventricular pacing when an intrinsic ventricular event is not detected within a specified VV interval, performs ventricular sensing, and inhibits the ventricular pacing when the intrinsic ventricular event is detected within the specified VV interval.

An intracardiac ventricular pacemaker having a motion sensor is configured to produce a motion signal including an atrial systolic event and a ventricular diastolic event indicating a passive ventricular filling phase, set a detection threshold to a first amplitude during an expected time interval of the ventricular diastolic event and to a second amplitude lower than the first amplitude after an expected time interval of the ventricular diastolic event. The pacemaker is configured to detect the atrial systolic event in response to the motion signal crossing the detection threshold and set an atrioventricular pacing interval in response to detecting the atrial systolic event.

A leadless pacing device for implanting into an atrium of a heart. The leadless device comprises an implant anchor for connecting the device to an inner wall of the atrium; a stimulator for a direct stimulation of the atrium; a sensor for sensing a ventricular activity of the heart corresponding to the direct stimulation of the atrium. Further aspects relate to a system comprising such leadless pacing device, a method and a computer program that may be executed by such leadless pacing device.

The engagement of the two atria via atrial pacing therapy is determined using one or more metrics based on monitored external electrical activity. For example, external electrical activity can be monitored during delivery of the atrial pacing therapy, right atrial and left atrial components can be generated based on the monitored external electrical activity, and one or more metrics can be generated based on the right atrial and left atrial components. One or more metrics can then be used to determine whether the atrial pacing therapy has biatrial engagement.

This invention discloses a method comprising locating a Koch triangle region in the right atrium of a patient's heart; securing at least one electrode of an implantable lead or device from the Koch triangle region to cardiac tissue for delivery of atrium-to-ventricle (VfA) cardiac therapy; and testing the position or depth of the at least one electrode to configure the VfA cardiac therapy. Locating the target implantation area in the Koch triangle region may include detecting atrial slow path potentials (ASP) or atrial pacing outputs.

Disclosed herein are implantable medical devices and systems, and methods for used therewith, that selectively perform atrial pacing at an atrial pacing rate that is faster than an intrinsic atrial rate of a patient while the patient is experiencing an atrial tachycardia or atrial fibrillation and the intrinsic atrial rate of the patient is within the specified range, to attempt to convert the arrhythmia to a normal sinus rhythm.

The present invention provides VFA delivery and implant region detection. A method is disclosed that includes locating a Koch triangle region in a right atrium of a patient's heart; securing at least one electrode of an implantable lead or device to heart tissue from the Koch triangle region to deliver atrium-to-ventricle (VfA) cardiac therapy; and testing a location or depth of the at least one electrode to configure the VfA cardiac therapy. Locating a target implant region in the Koch triangle region can include detecting an atrial slow pathway potential (ASP) or an atrial pacing output.